Hemab Therapeutics Holdings, Inc. balance sheet COAG

As of Jun 30, 2026, Hemab Therapeutics Holdings, Inc. had total assets of $467.8 million and total liabilities of $13.5 million. Stockholders' equity was $454.3 million. It held $457.5 million in cash and investments against $1.0 million of total debt, net cash of $456.4 million. The current ratio, current assets divided by current liabilities, was 35.85.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
Assets
Cash
237
Short-term investments
220
Cash and investments
457
Total current assets
464
Property and equipment, net
1
Total assets
468
Liabilities and equity
Accounts payable
6
Total current liabilities
13
Total liabilities
14
Stockholders' equity
454
Debt
Lease liabilities
1
Total debt
1
Net cash
456
Ratios
Current ratio
35.85x
Debt to equity
0.00x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
COAG (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
, Emerging growth company
SEC CIK
2114044

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.